Comment on a Risk Stratification Tool for Relapse After Intravenous-to-Subcutaneous Switching of Infliximab in Patients With Inflammatory Bowel Diseases

This publication has 10 references indexed in Scilit:

• A Risk Stratification Tool for Relapse After Intravenous-To-Subcutaneous Switching of Infliximab in Patients With Inflammatory Bowel Diseases
  American Journal of Gastroenterology, 2025
• Integrating early response biomarkers in pharmacokinetic models: A novel method to individualize the initial infliximab dose in patients with Crohn's disease
  Clinical and Translational Science, 2025
• A Comparison of Intravenous Infliximab Versus Subcutaneous Infliximab on Remission Rates, Safety, Costs, Patient Preferences in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis
  Gastro Hep Advances, 2024
• Early Infliximab Clearance Predicts Remission in Children with Crohn’s Disease
  Digestive Diseases and Sciences, 2022
• Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study
  Clinical Gastroenterology and Hepatology, 2022
• Dashboard-Driven Accelerated Infliximab Induction Dosing Increases Infliximab Durability and Reduces Immunogenicity
  Inflammatory Bowel Diseases, 2022
• Population pharmacokinetics of subcutaneous infliximab CT‐P13 in Crohn’s disease and ulcerative colitis
  Alimentary Pharmacology & Therapeutics, 2021
• Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease
  Gastroenterology, 2021
• Real‐World Infliximab Pharmacokinetic Study Informs an Electronic Health Record‐Embedded Dashboard to Guide Precision Dosing in Children with Crohn’s Disease
  Clinical Pharmacology & Therapeutics, 2020
• Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases
  Clinical Gastroenterology and Hepatology, 2019